Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.
GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Endoscopy. 2018 Mar;50(3):263-282. doi: 10.1055/s-0043-121144. Epub 2017 Nov 27.
Many studies have reported on laterally spreading tumors (LSTs), but systematic reviews of the data to determine their risk of containing submucosal invasion (SMI) are lacking. We systematically screened and analyzed the available literature to provide a more solid basis for evidence-based treatment.
We conducted a systematic search in PubMed, Embase, the Cochrane Library, and Scopus for published articles until July 2017. We estimated pooled prevalence or odds ratios (ORs) with 95 % confidence intervals (CIs), using random-effects models. We classified endoscopic subtypes into granular LST, which comprises the homogeneous and nodular mixed subtypes, and non-granular LST, which comprises the flat elevated and pseudodepressed subtypes.
We identified 2949 studies, of which 48 were included. Overall, 8.5 % (95 %CI 6.5 % - 10.5 %) of LSTs contained SMI. The risk of SMI differed among the LST subtypes: 31.6 % in non-granular pseudodepressed LSTs (95 %CI 19.8 % - 43.4 %), 10.5 % in granular nodular mixed LSTs (95 %CI 5.9 % - 15.1 %), 4.9 % in non-granular flat elevated LSTs (95 %CI 2.1 % - 7.8 %), and 0.5 % in granular homogenous LSTs (95 %CI 0.1 % - 1.0 %). SMI was more common in distally rather than in proximally located LSTs (OR 2.50, 95 %CI 1.24 - 5.02). The proportion of SMI increased with lesion size (10 - 19 mm, 4.6 %; 20 - 29 mm, 9.2 %; ≥ 30 mm, 16.5 %). The pooled prevalence of patients with one or more LSTs in the general colonoscopy population was 0.8 % (95 %CI 0.6 % - 1.1 %).
The majority of LSTs are non-invasive at the time of colonoscopic detection and can be treated with (piecemeal) endoscopic mucosal resection. Pretreatment diagnosis of endoscopic subtype, specifying areas of concern (nodule or depression), determines those LSTs at highest risk of containing SMI, where en bloc resection is the preferred therapy.
已有许多研究报告了侧向伸展性肿瘤(LST),但缺乏系统评价数据以确定其黏膜下浸润(SMI)的风险。我们系统地筛选和分析了现有文献,为循证治疗提供了更坚实的基础。
我们在 PubMed、Embase、Cochrane 图书馆和 Scopus 中进行了系统检索,检索截至 2017 年 7 月发表的文章。我们使用随机效应模型估计了合并的患病率或比值比(OR)及其 95%置信区间(CI)。我们将内镜下亚型分为颗粒状 LST,包括同质和结节混合亚型,以及非颗粒状 LST,包括平坦隆起和假凹陷亚型。
我们共检索到 2949 项研究,其中 48 项符合纳入标准。总体而言,8.5%(95%CI 6.5%至 10.5%)的 LST 存在 SMI。LST 亚型的 SMI 风险不同:非颗粒状假凹陷型 LST 为 31.6%(95%CI 19.8%至 43.4%),颗粒状结节混合型 LST 为 10.5%(95%CI 5.9%至 15.1%),非颗粒状平坦隆起型 LST 为 4.9%(95%CI 2.1%至 7.8%),颗粒状同质型 LST 为 0.5%(95%CI 0.1%至 1.0%)。远端 LST 比近端 LST 更常见 SMI(OR 2.50,95%CI 1.24 至 5.02)。随着病变大小的增加,SMI 的比例也增加(10-19mm,4.6%;20-29mm,9.2%;≥30mm,16.5%)。在普通结肠镜人群中,单个或多个 LST 患者的患病率为 0.8%(95%CI 0.6%至 1.1%)。
大多数 LST 在结肠镜检测时为非侵袭性,可采用(分片)内镜黏膜切除术治疗。术前诊断内镜下亚型,明确关注部位(结节或凹陷),可确定那些最有 SMI 风险的 LST,这些 LST 采用整块切除是首选治疗方法。